AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ascendiant Capital Keeps Buy Rating on Myomo, PT Lowered to $10.5
ByAinvest
Monday, Sep 22, 2025 6:01 am ET1min read
Ascendiant Capital Keeps Buy Rating on Myomo, PT Lowered to $10.5
Ascendiant Capital has maintained its buy rating on Myomo, Inc. (NYSEAM: MYO), despite a recent downward revision in the company's price target to $10.5. The investment research firm cited the company's innovative product line, MyoPro, which offers improved arm and hand function for patients with neurological disorders and upper-limb paralysis [1].MyoPro, a powered upper-limb orthosis, senses a patient's electromyography (EMG) signals through non-invasive sensors on the arm, restoring function to weakened or paralyzed limbs. This allows patients to perform activities of daily living such as feeding, carrying objects, and doing household tasks. MyoPro is directly sold to patients and billed to their insurance companies, with additional sales through orthotics and prosthetics providers, the veterans' administration, and other channels.
Ascendiant Capital's decision to maintain a buy rating reflects the company's strong market position and potential for growth. However, the price target revision suggests a more conservative outlook on the stock's valuation. Investors should closely monitor Myomo's financial performance and market developments to make informed decisions.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet